About Us: Leadership
Breaking Boundaries Takes Bold Leadership
Our experienced leadership team brings a proven track record in the discovery, development and commercialization of groundbreaking therapies that transform patient care in a variety of disease areas. Together, our leaders advance our culture of scientific rigor and an operational mindset, maintaining an unwavering focus on the discovery and development of therapies for the patients who stand to benefit most.
Josh Lehrer, M.Phil., M.D., FACC
Chief Executive Officer
Dr. Josh Lehrer is the chief executive officer at Graphite Bio. In this role, Dr. Lehrer bridges his clinical background as a practicing physician with decades of experience at global biopharmaceutical companies leading businesses and high-functioning teams across all stages of drug development.
Previously, Dr. Lehrer served as chief medical officer at Global Blood Therapeutics (GBT) where he led the innovative clinical development strategy for sickle cell disease treatment Voxelotor from pre-IND stages through commercial launch, including playing an integral role in raising over $1 billion to fund the product’s development and launch. At GBT, Dr. Lehrer also built a 45-member development organization and oversaw all clinical development and operations for the company during a period of rapid growth and pipeline advancement. Dr. Lehrer has also served in leadership roles at Genentech in clinical development and business development, as well as attending physician roles at Stanford University Medical Center and the Palo Alto Veteran’s Affairs Health System.
Dr. Lehrer earned his Doctor of Medicine at the University of California, San Francisco (UCSF), School of Medicine and completed his residency at UCSF in internal medicine. He holds an A.B. in Biochemical Sciences from Harvard University and a Master of Philosophy in Biological Sciences from the University of Cambridge. Dr. Lehrer served as a clinical and postdoctoral fellow in cardiovascular medicine at Stanford University and attended the Institute for Entrepreneurship at the Stanford Graduate School of Business.
Chief Technical Officer
Jerry Cacia is the chief technical officer at Graphite Bio. In this role, Mr. Cacia is responsible for leading the development of the overall manufacturing strategy and technical operations in support of Graphite Bio’s gene editing programs as they advance to the clinic. Mr. Cacia is advancing the development and implementation of a robust manufacturing strategy to ensure the advancement of Graphite Bio’s clinical programs and assure a clear and scalable path to patients.
Mr. Cacia has proven experience in the development of manufacturing processes and quality control systems across multiple therapeutic modalities. During his 32-year career at Genentech and Roche, he held various senior leadership positions in technical development, manufacturing, and quality. In his most recent position, Jerry served as head of global technical development at Roche during which time he supported a pipeline that included over 80 new molecular entities and more than 100 development projects in various stages, including a number of cell, gene and individualized neoantigen therapy programs.
Mr. Cacia holds a Bachelor’s of Science degree in Biological Sciences from the University of California at Santa Cruz.
Philip P. Gutry
Chief Business Officer, Head of Finance & Investor Relations
Philip Gutry serves as chief business officer, head of finance & investor relations at Graphite Bio. Mr. Gutry brings to this role extensive business development, strategy, finance and investor relations experience with a successful track record of raising capital and establishing partnerships for biotech companies.
Mr. Gutry most recently worked at Kronos Bio, a clinical-stage oncology company focused on targeting dysregulated transcription, where he served as chief business officer. In this role, he led the acquisition of Gilead’s spleen tyrosine kinase inhibitor portfolio, which transformed Kronos into a clinical-stage company and was the primary catalyst for raising $500M in equity capital, including the company’s Initial Public Offering. Previously, Mr. Gutry served in senior business development and finance roles at Regeneron Pharmaceuticals, MPM Capital and Gilead Sciences during which he led or managed over 30 transactions raising over $2 billion in equity, debt, and R&D funding. Mr. Gutry also serves on the Board of Directors at Cerecor Inc., a biopharmaceutical company focused on the development and commercialization of products in rare pediatric and orphan diseases.
Mr. Gutry received his A.B. in Earth Sciences from Dartmouth College and his M.B.A. in Healthcare Management from The Wharton School.
Katherine Vega Stultz
Chief Operating Officer
Katherine Stultz is the chief operating officer at Graphite Bio. Ms. Stultz is an entrepreneurially driven corporate leader with broad enterprise experience serving in leadership roles across the operations, clinical development and commercial functions of leading global healthcare companies. She brings to the role a proven track record of success in building brands that have generated over $1B in annual revenue.
Prior to joining Graphite Bio, Ms. Stultz spent 15 years at Celgene Corporation during a period of exponential growth for the company and its products. She served most recently as general manager in the Spain/Portugal market where she managed P&L and built a fully integrated team, ultimately growing the business and significantly improving operating margins. Earlier at Celgene, Ms. Stultz served as corporate vice president, global project leadership, hematology and oncology, directing the clinical project organization worldwide and overseeing over 30 mid/late stage clinical programs. Katherine began her career at Eli Lilly & Company and ConvaTec, a Bristol-Myers Squibb company, where she progressed through a series of product development, project management, sales, and marketing positions.
Ms. Stultz holds a Bachelor of Science degree in Mechanical Engineering (Biomedical Applications) from Cornell University and has attended executive leadership development programs at the Darden School of Business, University of Virginia, IESE Business School in Barcelona, Spain, and the International Institute for Management Development (IMD) in Switzerland.